Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Ashley Bonnell

Nurse Practitioner, Family Knoxville, TN Nurse Practitioner

NPI 1013521285 CMS profile 10873260

2060 Lakeside Centre Way, Knoxville, TN 37922

Open in the dashboard

General payments

$49,226

580 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ashley Bonnell of Knoxville, TN is reported in the CMS Open Payments database as having received $49,226 across 580 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,158 92
2024 General $19,772 156
2023 General $15,162 143
2022 General $4,834 182
2021 General $300 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ashley Bonnell
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Ashley Bonnell were reported at $9,158. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Ashley Bonnell Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $300 $124 $35–$379 $132
2022 $4,834 $141 $44–$430 $149
2023 $15,162 $154 $49–$476 $160
2024 $19,772 $165 $51–$504 $164
2025 $9,158 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. EMD Serono, Inc. $34,272 139 payments
  2. E.R. Squibb & Sons, L.L.C. $4,100 9 payments
  3. Biogen, Inc. $2,094 74 payments
  4. Novartis Pharmaceuticals Corporation $1,431 66 payments
  5. Celgene Corporation $1,263 48 payments
  6. Alexion Pharmaceuticals, Inc. $809 26 payments
  7. Genzyme Corporation $773 19 payments
  8. TG Therapeutics, Inc. $654 26 payments
  9. Genentech USA, Inc. $520 25 payments
  10. Amgen Inc. $479 21 payments
  11. Other $2,830 127 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $32,307 19 payments
  2. Food and Beverage $14,899 543 payments
  3. Travel and Lodging $978 8 payments
  4. Consulting Fee $650 3 payments
  5. Education $392 7 payments
Products named General payments · program years 2021–2025
  1. Mavenclad Neurology $29,832 24 payments
  2. ZEPOSIA $5,166 55 payments
  3. TYSABRI $1,077 34 payments
  4. KESIMPTA Neurology $814 39 payments
  5. VUMERITY Neurology $715 23 payments
  6. MAVENCLAD Neurology $696 30 payments
  7. BRIUMVI $654 26 payments
  8. KESIMPTA Neuroscience $596 26 payments
  9. VUMERITY Neurology $578 21 payments
  10. ULTOMIRIS $479 14 payments
  11. Other $5,432 239 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

626

Median for Nurse Practitioner: 389

Drug cost

$1,676,782

Median for Nurse Practitioner: $21,885

Branded share of claims

54.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Kesimpta Pen Ofatumumab Brand 96 $934,151
Zeposia Ozanimod Hydrochloride Brand 16 $202,664
Tysabri Natalizumab Brand 17 $141,590
Avonex (4 Pack) Interferon Beta-1a Brand 14 $134,426
Aubagio Teriflunomide Brand 13 $120,967
Teriflunomide Generic 29 $56,847
Dalfampridine Er Dalfampridine Brand 64 $47,643
Glatopa Glatiramer Acetate Brand 13 $31,980
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 39 $1,323
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 20 $1,001

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Mavenclad
  • EMD Serono, Inc. $13,106
$13,106 — —
ZEPOSIA
  • E.R. Squibb & Sons, L.L.C. $2,625
  • Celgene Corporation $569
$3,194 16 —
KESIMPTA
  • Novartis Pharmaceuticals Corporation $392
$392 96 —
VUMERITY
  • Biogen, Inc. $282
$282 — —
BRIUMVI
  • TG Therapeutics, Inc. $163
$163 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

580 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record